All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group

Diurnal completes IPO in dark days of December


Diurnal Group, a UK company developing drugs to treat rare chronic hormonal imbalances, completed its Aim IPO for £25m on Monday, gaining a £75m market cap.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree